KLRK1 and congenital rubella syndrome: Studies also have found that another side effect of FLT3scFv/NKG2D CAR-T cell therapy may be cytokine release syndrome (CRS), while this adverse effect did not enhanced by gilteritinib pretreatment in vitro.